2025-524446-10-00招募中1 期
Phase 1 open label trial of MST-0312 alone and in combination in subjects with solid malignancies
Mestag Therapeutics Limited7 个研究点 分布在 1 个国家目标入组 42 人开始时间: 2026年4月1日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 42
- 试验地点
- 7
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Colin Lunt
Scientific
Mestag Therapeutics Limited
研究点 (7)
Loading locations...
相似试验
招募中
1 期
A Phase 1 Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAS-004, a MEK (1/2) Inhibitor, in Patients with MAPK Pathway-driven Advanced Solid Tumors with a Documented RAS, NF1, or RAF Mutation or Patients who have Failed BRAF/MEK Inhibition2024-510900-34-00Pasithea Therapeutics Corp.24
尚未招募
不适用
A clinical trail to Check if Magnetic Devices Can Safely and Effectively Reconnect Blocked or Disconnected Bile Ducts After Gallbladder Surgery or Liver Transplant.CTRI/2025/08/093837Dr Sanjay Raput20
招募中
1 期
A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid TumorsNCT07298772Suzhou Suncadia Biopharmaceuticals Co., Ltd.198
招募中
1 期
U69-CART-Cells For R/R T-ALLNCT07350863The First Affiliated Hospital of Soochow University12
招募中
1 期
Evaluation of MTX-463 Administered Subcutaneously in Healthy Adult MalesNCT07450521Mediar Therapeutics8